- Home
- ALVR vs VNRX Comparison
ALVR vs VNRX Comparison
Compare ALVR & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVR
- VNRX
- Stock Information
- Founded
- ALVR 2013
- VNRX N/A
- Country
- ALVR United States
- VNRX United States
- Employees
- ALVR N/A
- VNRX N/A
- Industry
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ALVR Health Care
- VNRX Health Care
- Exchange
- ALVR Nasdaq
- VNRX Nasdaq
- Market Cap
- ALVR 48.8M
- VNRX 56.5M
- IPO Year
- ALVR 2020
- VNRX N/A
- Fundamental
- Price
- ALVR $9.63
- VNRX $0.55
- Analyst Decision
- ALVR
- VNRX Strong Buy
- Analyst Count
- ALVR 0
- VNRX 4
- Target Price
- ALVR N/A
- VNRX $4.17
- AVG Volume (30 Days)
- ALVR 22.4K
- VNRX 103.1K
- Earning Date
- ALVR 03-14-2025
- VNRX 03-24-2025
- Dividend Yield
- ALVR N/A
- VNRX N/A
- EPS Growth
- ALVR N/A
- VNRX N/A
- EPS
- ALVR N/A
- VNRX N/A
- Revenue
- ALVR N/A
- VNRX $1,285,827.00
- Revenue This Year
- ALVR N/A
- VNRX $71,446.31
- Revenue Next Year
- ALVR N/A
- VNRX N/A
- P/E Ratio
- ALVR N/A
- VNRX N/A
- Revenue Growth
- ALVR N/A
- VNRX 97.50
- 52 Week Low
- ALVR $7.96
- VNRX $0.43
- 52 Week High
- ALVR $24.15
- VNRX $1.10
- Technical
- Relative Strength Index (RSI)
- ALVR 45.63
- VNRX 41.65
- Support Level
- ALVR $9.55
- VNRX $0.56
- Resistance Level
- ALVR $10.41
- VNRX $0.61
- Average True Range (ATR)
- ALVR 0.44
- VNRX 0.04
- MACD
- ALVR 0.05
- VNRX -0.00
- Stochastic Oscillator
- ALVR 22.77
- VNRX 2.67
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.